BRIDGE BIOTHERAPEUTICS, INC.
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 42
- Market Cap
- -
- Website
- http://www.bridgebiorx.com
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)β’ Click on a phase to view related trials
First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
- Conditions
- EGFR Mutant Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05920135
- Locations
- π°π·
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
π°π·Samsung Medical Center, Seoul, Korea, Republic of
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT05483907
- Locations
- πΊπΈ
Pulmonary Associates P.A., Phoenix, Arizona, United States
πΊπΈSouthern Arizona VA Health Care System - NAVREF - PPDS, Tucson, Arizona, United States
πΊπΈKeck Medical Center of USC, Los Angeles, California, United States
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
- Conditions
- NSCLC
- Interventions
- Drug: BBT-176, QDDrug: BBT-176, BID
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04820023
- Locations
- π°π·
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
π°π·Samsung Medical Center, Seoul, Korea, Republic of
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: BBT-401-1S or Placebo
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04596293
- Locations
- πΊπΈ
Premier Gastroenterology, Little Rock, Arkansas, United States
πΊπΈSaini Surinder S MD, Fountain Valley, California, United States
πΊπΈGastro Care Institute, Lancaster, California, United States
Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04478825
- Locations
- π³πΏ
P3 Research, Wellington, New Zealand
- Prev
- 1
- 2
- Next